Clinical Trials

DermatologicGastrointestinal

89 enrolled 24 charts

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT04447755 2025-10-03

E7080-G000-231

127 enrolled 29 charts

Recurrence

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Gynecologic

Recurrence, Endometrial Neoplasms

NCT04716933 2025-09-09

LEAP-006

201 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

57 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

58 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03976375 2025-08-15

LEAP-008

Phase 2 Active not recruiting

422 enrolled 30 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

6 enrolled 11 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT02678780 2025-07-24

TALENT

123 enrolled 37 charts

EndocrineNET

Neuroendocrine Tumors

NCT02720068 2025-05-30

MK-4280-001

481 enrolled 36 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT03609359 2025-04-16

Lenva+Pembro

29 enrolled 20 charts

Stomach Neoplasms

NCT04676412 2025-04-04

LEAP-007

107 enrolled 24 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

343 enrolled 25 charts

Genitourinary

Carcinoma, Renal Cell

NCT04267120 2025-03-21

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Phase 2 Terminated

11 enrolled 16 charts

Genitourinary

Carcinoma, Renal Cell

NCT04401800 2025-03-10

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

64 enrolled 23 charts

Carcinoma, Hepatocellular

NCT03477175 2025-01-07

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

40 enrolled 13 charts

Other solid neoplasm

Solid Tumors

NCT04154189 2024-07-22

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

81 enrolled 22 charts

Sarcoma

Recurrence, Osteosarcoma

NCT03418922 2024-06-20

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

30 enrolled 28 charts

Carcinoma, Hepatocellular

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

29 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT03321630 2024-03-27

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

24 enrolled 10 charts

Stomach Neoplasms

NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

3 enrolled 9 charts

CNSEndocrine

Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT03006926 2023-12-13

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

104 enrolled 41 charts

Carcinoma, Hepatocellular

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

64 enrolled 29 charts

CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

357 enrolled 28 charts 2 FDA

Tumor-Agnostic

Neoplasms

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

117 enrolled 32 charts

Sarcoma

Neoplasms, Osteosarcoma

NCT00121719 2023-06-22

An Open Label Dose Escalation Study Of E7080

82 enrolled 34 charts

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT01111461 2023-06-22

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

133 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT01133756 2023-06-22

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Phase 1/2 Terminated

7 enrolled 6 charts

Gynecologic

Ovarian Neoplasms

NCT01268293 2023-06-22

A Study of E7080 in Subjects With Solid Tumor

9 enrolled 6 charts

Tumor-Agnostic

Neoplasms

NCT01321554 2023-06-22

SELECT